Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease

Vaccine

Volumn 29, Issue 37, 2011, Pages 6301-6312

  Moraes, Theo J ^a,b,c   Lin, Gloria H Y ^a   Wen, Tao ^a   Watts, Tania H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

4 1BBL; Adenovirus vectors; CD8 T cell; Costimulation; Influenza; Respiratory infection

Indexed keywords

ADENOVIRUS VECTOR; CD137 LIGAND; INFLUENZA VACCINE; VIRUS NUCLEOPROTEIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; INFLUENZA; INFLUENZA VIRUS; LOW DRUG DOSE; MALE; MORTALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SINGLE DRUG DOSE;

4-1BB LIGAND; ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; BONE MARROW CELLS; CD8-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED C57BL; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT DISEASES; VIRAL VACCINES;

EID: 80051556033     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.022     Document Type: Article

References (71)

1. Salomon R., Webster R.G. The influenza virus enigma. Cell 2009, 136(February (3)):402-410.
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(January (2)):179-186.
3. McCullers J.A. Preparing for the next influenza pandemic. Pediatr Infect Dis J 2008, 27(October (10 Suppl.)):S57-S59.
4. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459(June (7249)):931-939.
5. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361(November (20)):1935-1944.
6. Doherty P.C., Turner S.J., Webby R.G., Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 2006, 7(May 5):449-455.
7. Wong P., Pamer E.G. CD8 T cell responses to infectious pathogens. Annu Rev Immunol 2003, 21:29-70.
8. McMichael A.J., Gotch F.M., Dongworth D.W., Clark A., Potter C.W. Declining T-cell immunity to influenza, 1977-82. Lancet 1983, 2(October (8353)):762-764.
9. Moskophidis D., Kioussis D. Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med 1998, 188(July (2)):223-232.
10. Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006, 12(January (1)):48-54.
11. Gorman O.T., Bean W.J., Kawaoka Y., Donatelli I., Guo Y.J., Webster R.G. Evolution of influenza A virus nucleoprotein genes: implications for the origins of H1N1 human and classical swine viruses. J Virol 1991, 65(July (7)):3704-3714.
12. Bui H.H., Peters B., Assarsson E., Mbawuike I., Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci USA 2007, 104(January (1)):246-251.
13. Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985, 82(March (6)):1785-1789.
14. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23(November (46-47)):5404-5410.
15. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(March (5102)):1745-1749.
16. Roy S., Kobinger G.P., Lin J., Figueredo J., Calcedo R., Kobasa D., et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 2007, 25(September (39-40)):6845-6851.
17. Andrew M.E., Coupar B.E. Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand J Immunol 1988, 28(July (1)):81-85.
18. Lawson C.M., Bennink J.R., Restifo N.P., Yewdell J.W., Murphy B.R. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol 1994, 68(June (6)):3505-3511.
19. Stitz L., Schmitz C., Binder D., Zinkernagel R., Paoletti E., Becht H. Characterization and immunological properties of influenza A virus nucleoprotein (NP): cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection. J Gen Virol 1990, 71(May (Pt 5)):1169-1179.
20. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol Ther 2009, 17(August (8)):1333-1339.
21. Seregin S.S., Amalfitano A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin Biol Ther 2009, 9(December (12)):1521-1531.
22. Goodwin R.G., Din W.S., Davis-Smith T., Anderson D.M., Gimpel S.D., Sato T.A., et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993, 23(October (10)):2631-2641.
23. Futagawa T., Akiba H., Kodama T., Takeda K., Hosoda Y., Yagita H., et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002, 14(March (3)):275-286.
24. Kwon B.S., Kestler D.P., Eshhar Z., Oh K.O., Wakulchik M. Expression characteristics of two potential T cell mediator genes. Cell Immunol 1989, 121(July (2)):414-422.
25. Pollok K.E., Kim Y.J., Zhou Z., Hurtado J., Kim K.K., Pickard R.T., et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993, 150(February (3)):771-781.
26. Wang C., Lin G.H., McPherson A.J., Watts T.H. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009, 229(May (1)):192-215.
27. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
28. Kwon B.S., Hurtado J.C., Lee Z.H., Kwack K.B., Seo S.K., Choi B.K., et al. Immune responses in 4-1BB (CD137)-deficient mice. J Immunol 2002, 168(June (11)):5483-5490.
29. Cottey R., Rowe C.A., Bender B.S. Influenza virus. Curr Protoc Immunol 2001, (May). Chapter 19:Unit 19.1.
30. Bertram E.M., Lau P., Watts T.H. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 2002, 168(April (8)):3777-3785.
31. Lin G.H., Sedgmen B.J., Moraes T.J., Snell L.M., Topham D.J., Watts T.H. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol 2009, 182(January (2)):934-947.
32. Santosuosso M., McCormick S., Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005, 18(2):283-291.
33. Hoelscher M.A., Singh N., Garg S., Jayashankar L., Veguilla V., Pandey A., et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis 2008, 197(April (8)):1185-1188.
34. Van Kampen K.R., Shi Z., Gao P., Zhang J., Foster K.W., Chen D.T., et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005, 23(January (8)):1029-1036.
35. Townsend A.R., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986, 44(March (6)):959-968.
36. Hartman Z.C., Appledorn D.M., Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008, 132(March (1-2)):1-14.
37. Lamere M.W., Lam H.T., Moquin A., Haynes L., Lund F.E., Randall T.D., et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol (February) 2011, 186(April (7)):4331-4339. Epub 2011 Feb 25.
38. Bossen C., Ingold K., Tardivel A., Bodmer J.L., Gaide O., Hertig S., et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 2006, 281(May (20)):13964-13971.
39. Choi B.K., Kim Y.H., Kwon P.M., Lee S.C., Kang S.W., Kim M.S., et al. 4-1BB functions as a survival factor in dendritic cells. J Immunol 2009, 182(April (7)):4107-4115.
40. Kim D.H., Chang W.S., Lee Y.S., Lee K.A., Kim Y.K., Kwon B.S., et al. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J Immunol 2008, 180(February (4)):2062-2068.
41. Betts M.R., Brenchley J.M., Price D.A., De Rosa S.C., Douek D.C., Roederer M., et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281(October (1-2)):65-78.
42. Graham M.B., Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 1997, 186(December (12)):2063-2068.
43. Fishaut M., Tubergen D., McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980, 96(February (2)):179-186.
44. Doherty P.C., Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 2008, 118(October (10)):3273-3275.
45. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3(1):e1401.
46. Lee L.Y., Ha do L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008, 118(October (10)):3478-3490.
47. Moon J.J., Chu H.H., Pepper M., McSorley S.J., Jameson S.C., Kedl R.M., et al. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007, 27(August (2)):203-213.
48. Harty J.T., Badovinac V.P. Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 2008, 8(February (2)):107-119.
49. Pulle G., Vidric M., Watts T.H. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol 2006, 176(March (5)):2739-2748.
50. DeBenedette M.A., Wen T., Bachmann M.F., Ohashi P.S., Barber B.H., Stocking K.L., et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 1999, 163(November (9)):4833-4841.
51. Bukczynski J., Wen T., Ellefsen K., Gauldie J., Watts T.H. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci USA 2004, 101(February (5)):1291-1296.
52. Gallichan W.S., Johnson D.C., Graham F.L., Rosenthal K.L. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J Infect Dis 1993, 168(September (3)):622-629.
53. Gallichan W.S., Rosenthal K.L. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996, 184(November (5)):1879-1890.
54. Belyakov I.M., Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J Immunol 2009, 183(December (11)):6883-6892.
55. Blank F., Stumbles P., von Garnier C. Opportunities and challenges of the pulmonary route for vaccination. Expert Opin Drug Deliv 2011, 8(May (5)):547-563. Epub 2011 Mar 26.
56. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173(November (10)):6357-6365.
57. Guy B., Fourage S., Hessler C., Sanchez V., Millet M.J. Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone. Clin Diagn Lab Immunol 1998, 5(September (5)):732-736.
58. McCormick S., Shaler C.R., Xing Z. Pulmonary mucosal dendritic cells in T-cell activation: implications for TB therapy. Expert Rev Respir Med 2011, 5(February (1)):75-85.
59. Wang C., Wen T., Routy J.P., Bernard N.F., Sekaly R.P., Watts T.H. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. J Immunol 2007, 179(December (12)):8252-8263.
60. Lin G.H.Y., Liu Y., Amabagala T., Kwon B.S., Ohashi P.S., Watts T.H. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of preestablished tumor in mice. PLoS One 2010, 5(June (6)):e11003.
61. Christensen J.P., Doherty P.C., Branum K.C., Riberdy J.M. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory. J Virol 2000, 74(December (24)):11690-11696.
62. Bertram E.M., Dawicki W., Sedgmen B., Bramson J.L., Lynch D.H., Watts T.H. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol 2004, 172(January (2)):981-988.
63. Guillonneau C., Mintern J.D., Hubert F.X., Hurt A.C., Besra G.S., Porcelli S., et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009, 106(March (9)):3330-3335.
64. Niu L., Strahotin S., Hewes B., Zhang B., Zhang Y., Archer D., et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007, 178(April (7)):4194-4213.
65. Wyde P.R., Couch R.B., Mackler B.F., Cate T.R., Levy B.M. Effects of low- and high-passage influenza virus infection in normal and nude mice. Infect Immun 1977, 15(January (1)):221-229.
66. Wells M.A., Albrecht P., Ennis F.A. Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. J Immunol 1981, 126(March (3)):1036-1041.
67. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80(February (4)):1959-1964.
68. Holman D.H., Wang D., Raja N.U., Luo M., Moore K.M., Woraratanadharm J., et al. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 2008, 26(May (21)):2627-2639.
69. Lo C.Y., Wu Z., Misplon J.A., Price G.E., Pappas C., Kong W.P., et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 2008, 26(April (17)):2062-2072.
70. Hoelscher M.A., Jayashankar L., Garg S., Veguilla V., Lu X., Singh N., et al. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Ther 2007, 82(December (6)):665-671.
71. Lynch D.H. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008, April (222):277-286.